Related Experiment Video

Updated: Feb 23, 2026

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas
09:21

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas

Published on: September 13, 2019

7.6K

Olaratumab for the treatment of advanced soft tissue sarcoma

Scott H Okuno1, Avudaiappan Maran2, Steven I Robinson1

  • 1a Department of Oncology , Mayo Clinic , Rochester , MN USA.

Expert Review of Anticancer Therapy
|September 2, 2017
PubMed
Abstract

Insights

Olaratumab combined with doxorubicin offers improved survival for advanced soft tissue sarcoma (STS) patients. This novel treatment targets platelet-derived growth factor receptor alpha (PDGFR-α), representing a significant advancement in STS therapy.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Soft tissue sarcoma (STS) is a rare cancer with limited treatment options.
  • Platelet-derived growth factor receptor alpha (PDGFR-α) is implicated in STS progression.

Purpose of the Study:

  • To review the development and efficacy of olaratumab for STS treatment.
  • To assess the combination therapy of olaratumab and doxorubicin.

Main Methods:

  • Literature review of PubMed articles using keywords: 'platelet derived growth factor', 'receptor', and 'soft tissue sarcoma'.
  • Analysis of published studies on olaratumab, focusing on its use in STS.

Main Results:

  • Olaratumab, a monoclonal antibody targeting PDGFR-α, demonstrated improved overall survival in advanced/metastatic STS when combined with doxorubicin.
  • The combination therapy showed better outcomes compared to doxorubicin alone.

Conclusions:

  • Olaratumab is a well-tolerated drug for STS treatment.
  • The combination of olaratumab and doxorubicin represents a promising therapeutic strategy for advanced STS.
  • A Phase III confirmatory study is anticipated to further validate these findings.
Keywords:
Soft tissue sarcomachemotherapyolaratumabplatelet derived growth factorplatelet derived growth factor receptor

More Related Videos

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.9K
Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model13:41

Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model

Published on: January 13, 2023

2.9K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K